Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and ...
HASBROUCK HEIGHTS, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their …